Search Results

Showing results 981 - 990 for leonard

Parkinson’s Disease: Lost in Translation | Feil Family Brain & Mind Research Institute

..., M.D./Ph.D., Leonard and Madlyn Abramson Professor in Neurodegenerative Diseases/Director, Institute...

https://brainandmind.weill.cornell.edu/events/parkinson%E2%80%99s-disease-lost-translation

ASCT-related toxicities for patients with MCL | Sandra and Edward Meyer Cancer Center

... to aggressive therapy in Mantle Cell Lymphoma Is the open mouth mightier than the needle? Leonard...

https://meyercancer.weill.cornell.edu/news/2017-08-08/asct-related-toxicities-patients-mcl

Skin-derived TSLP systemically expands regulatory T cells. | Artis Lab

..., Siracusa MC, Leonard WJ, Naji A, Wu GF, Artis D, Kambayashi T Journal J Autoimmun Volume 79 Pagination 39...

https://artislab.weill.cornell.edu/publications/skin-derived-tslp-systemically-expands-regulatory-t-cells

Skin-derived TSLP systemically expands regulatory T cells. | The Jill Roberts Institute for Research in Inflammatory Bowel Disease

..., Satake, A, Harrison, VSanoe, Tanaka, Y, Archambault, AS, Kim, BS, Siracusa, MC, Leonard, WJ, Naji...

https://robertsinstitute.weill.cornell.edu/publications/skin-derived-tslp-systemically-expands-regulatory-t-cells

BCL6 Antagonizes NOTCH2 to Maintain Survival of Human Follicular Lymphoma Cells. | Cerchietti Research Lab

..., Leonard JP, Zweidler-McKay PA, Maillard I, Elemento O, Ci W, Aifantis I, Melnick A Journal Cancer...

https://cerchiettilab.weill.cornell.edu/publications/bcl6-antagonizes-notch2-maintain-survival-human-follicular-lymphoma-cells

Response to second-line therapy defines the potential for cure in patients with recurrent diffuse large B-cell lymphoma: implications for the development of novel therapeutic strategies. | Cerchietti Research Lab

... A, Furman R, Ruan J, Shore T, Schuster M, Cerchietti L, Melnick A, Coleman M, Leonard JP Journal Clin...

https://cerchiettilab.weill.cornell.edu/publications/response-second-line-therapy-defines-potential-cure-patients-recurrent-diffuse-large-b

Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma. | Cerchietti Research Lab

..., Cho HJe, Abbott J, Tam W, Du W, Leonard JP, Elemento O, Cerchietti L, Cierpicki T, Xue F...

https://cerchiettilab.weill.cornell.edu/publications/rationally-designed-bcl6-inhibitors-target-activated-b-cell-diffuse-large-b-cell

Selective targeting of BCL6 induces oncogene addiction switching to BCL2 in B-cell lymphoma. | Cerchietti Research Lab

... A, Tam W, Martin P, Leonard J, Melnick A, Cerchietti L Journal Oncotarget Volume 7 Issue 3...

https://cerchiettilab.weill.cornell.edu/publications/selective-targeting-bcl6-induces-oncogene-addiction-switching-bcl2-b-cell-lymphoma

Combinatorial epigenetic therapy in diffuse large B cell lymphoma pre-clinical models and patients. | Cerchietti Research Lab

... S-N, Ahn H, Patel J, Elstrom R, Ruan J, Furman R, Leonard J, Cerchietti L, Martin P Journal Clin...

https://cerchiettilab.weill.cornell.edu/publications/combinatorial-epigenetic-therapy-diffuse-large-b-cell-lymphoma-pre-clinical-models-and

Acknowledgements | Joint Clinical Trials Office

... different ways we offer our sincerest gratitude and thanks to you all. John Leonard, Mary Simmerling...

https://jcto.weill.cornell.edu/about/acknowledgements

Showing results 981 - 990 for leonard